| |
HCC, N = 17
|
No HCC, N = 103
|
p overall
|
|---|
|
Age 65
|
0.357
|
|
<65
|
11 (64.7%)
|
80 (77.7%)
|
|
> 65
|
6 (35.3%)
|
23 (22.3%)
|
|
Sex
|
0.735
|
|
F
|
2 (11.8%)
|
20 (19.4%)
|
|
M
|
15 (88.2%)
|
83 (80.6%)
|
|
AFP (ng/ml)
|
165 [6.70; 435]
|
7.10 [4.00; 39.1]
|
0.009
|
|
Waiting_time (days)
|
230 [31.0; 394]
|
211 [75.5; 344]
|
0.934
|
|
D (mm)
|
43.4 (20.0)
|
31.5 (20.6)
|
0.035
|
|
MELD
|
1.000
|
|
MELD ≤ 15
|
12 (80.0%)
|
59 (72.0%)
|
|
MELD = 15–30
|
2 (13.3%)
|
15 (18.3%)
|
|
MELD > 30
|
1 (6.67%)
|
8 (9.76%)
|
|
preTreat
|
1.000
|
|
No pre-treatment
|
6 (35.3%)
|
39 (37.9%)
|
|
Pre-treatment
|
11 (64.7%)
|
64 (62.1%)
|
|
N
|
0.012
|
|
N = 1
|
1 (12.5%)
|
58 (63.0%)
|
|
N = 1–3
|
5 (62.5%)
|
25 (27.2%)
|
|
N > 3
|
2 (25.0%)
|
9 (9.78%)
|
|
Grade
|
0.045
|
|
1
|
0 (0.00%)
|
23 (43.4%)
|
|
2
|
5 (83.3%)
|
28 (52.8%)
|
|
3
|
1 (16.7%)
|
2 (3.77%)
|
|
Asan
|
< 0.001
|
|
Exceeding
|
12 (70.6%)
|
23 (22.3%)
|
|
Fulfilling
|
5 (29.4%)
|
80 (77.7%)
|
|
AFP score
|
< 0.001
|
|
> 2
|
12 (70.6%)
|
14 (15.9%)
|
|
≤ 2
|
5 (29.4%)
|
74 (84.1%)
|
|
MC
|
0.001
|
|
Exceeding
|
13 (76.5%)
|
33 (32.0%)
|
|
Fulfilling
|
4 (23.5%)
|
70 (68.0%)
|
|
UTS
|
< 0.001
|
|
Exceeding
|
13 (76.5%)
|
21 (20.4%)
|
|
Fulfilling
|
4 (23.5%)
|
82 (79.6%)
|
- Data are shown as the average and standard deviation (round brackets) for normally distributed data and as the median and quantiles (square brackets) for non-normally distributed data
- AFP alpha-feto protein in ng/ml, D diameter of the largest tumor in mm, MELD model of end-stage liver disease, N number of tumors, MC Milan criteria, UTS up-to-seven criteria
